Study of the in vitro and in vivo metabolism of the tryptamine 5-MeO-MiPT using human liver microsomes and real case samples.

Grafinger, Katharina; Hädener, Marianne; König, Stefan; Weinmann, Wolfgang (2018). Study of the in vitro and in vivo metabolism of the tryptamine 5-MeO-MiPT using human liver microsomes and real case samples. Drug testing and analysis, 10(3), pp. 562-574. Wiley 10.1002/dta.2245

Preview

Text Grafinger_et_al-2017-Drug_Testing_and_Analysis.pdf - Accepted Version Available under License Publisher holds Copyright. Download (1MB) | Preview

The synthetic tryptamine 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT) has recently been abused as a hallucinogenic drug in Germany and Switzerland. This study presents a case of 5-MeO-MiPT intoxication and the structural elucidation of metabolites in pooled human liver microsomes (pHLM), blood, and urine. Microsomal incubation experiments were performed using pHLM to detect and identify in vitro metabolites. In August 2016, the police encountered a naked man, agitated and with aggressive behavior on the street. Blood and urine samples were taken at the hospital and his premises was searched. The obtained blood and urine samples were analyzed for in vivo metabolites of 5-MeO-MiPT using LC-high resolution MS/MS (LC-HR-MS/MS). The confiscated pills and powder samples were qualitatively analyzed using FTIR, GC-MS, LC-HR-MS/MS and NMR. 5-MeO-MiPT was identified in two of the seized powder samples. General unknown screening detected cocaine, cocaethylene, methylphenidate, ritalinic acid and 5-MeO-MiPT in urine. Seven different in vitro phase I metabolites of 5-MeO-MiPT were identified. In the forensic case samples, four phase I metabolites could be identified in blood and seven in urine. The five most abundant metabolites were formed by demethylation and hydroxylation of the parent compound. 5-MeO-MiPT concentrations in the blood and urine sample were found to be 160 ng/mL and 3380 ng/mL, respectively. Based on the results of this study we recommend metabolites 5-methoxy-N-isopropyltryptamine (5-MeO-NiPT), 5-hydroxy-N-methyl-N-isopropyltryptamine (5-OH-MiPT), 5-methoxy-N-methyl-N-isopropyltryptamine-N-oxide (5-MeO-MiPT-N-oxide) and hydroxy-5-methoxy-N-methyl-N-isopropyltryptamine (OH-5-MeO-MiPT) as biomarkers for the development of new methods for the detection of 5-MeO-MiPT consumption, as they have been present in both blood and urine samples.

Interest & Impact

Downloads

655 since deposited on 07 Aug 2017
260 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item